ABSTRACT
Busulfan (Bu) is widely used in conditioning regimens before allogeneic hematopoietic cell transplantation, with variable metabolism due to interindividual differences of pharmacokinetics (PK). The purpose of this study was to correlate pharmacokinetics and clinical outcomes. Lower-AUC, in range-AUC and higher-AUC were defined as ±25% of the targeted Bu-AUC. In 2019, we changed Bu dosing from 4×/day (Bu-4) to 1×/day (Bu-1) for ease of application. AUC-target range was reached in 46% of patients; 40% were in low-AUC and 14% in high-AUC. Among all toxicities, viral and fungal infections were significantly more frequent in high-AUC compared with low-AUC (20% vs. 8%; p = 0.01 and 37% vs. 17%; p = 0.03). Bu-1 showed lower PK values (66% vs. 36% of Bu-4 in low-AUC; p < 0.01) and higher incidence of mucositis (p = 0.02). Long-term outcomes at 2 years showed a higher non-relapse mortality (NRM) (p < 0.01) and higher relative risk of death in the high-AUC group compared to the other groups. Cumulative incidence of relapse and acute/chronic GvHD were not significantly different. The optimal cut-off in Bu-AUC associated with low NRM was 969 µmol/l*min (ROC AUC 0.67, sensitivity 0.86 and specificity 0.47) for Bu-4. In conclusion, low-AUC BU-PK seems of benefit regarding NRM and survival.
Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Adult , Area Under Curve , Busulfan , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Recurrence , Transplantation Conditioning/adverse effectsABSTRACT
We report the occurrence of immune thrombocytopenia (ITP) in a 77-year-old man a few days after receiving the first dose of the COVID-19 mRNA vaccine tozinameran (Comirnaty®). The patient was treated with systemic corticosteroids, intravenous immunoglobulins and eltrombopag. He elected to proceed with the second dose of tozinameran 14 weeks after the first and his platelet count remained stable under a tapered eltrombopag dose. To our knowledge, this is the first case in which a second tozinameran dose has been administered to a patient who developed presumed secondary ITP after the first vaccination. We also report global pharmacovigilance data for the occurrence of ITP after vaccination with tozinameran.
Subject(s)
COVID-19 , Purpura, Thrombocytopenic, Idiopathic , Aged , COVID-19 Vaccines , Humans , Pharmacovigilance , Purpura, Thrombocytopenic, Idiopathic/chemically induced , SARS-CoV-2 , Vaccines, Synthetic , mRNA VaccinesABSTRACT
BACKGROUND/AIMS: Because of high vaccination rates, population immunity against measles increased in the western world. Nevertheless, outbreaks are still observed. The aim of this article is to document and describe the natural course of dermatological manifestations and compare it with the literature. METHODS: After detecting a measles index case, the dermatological onset of the disease in the non-vaccinated siblings was prospectively monitored and documented with a digital camera. RESULTS: Our findings show that dermatological symptoms are only limited consistently from one case to another and described heterogeneously in the literature as well. CONCLUSION: Dermatological manifestations do not seem conclusive in our clinical data set as well as in the literature. Especially the exact onset of the Koplik spots should be further explored in detail. In future, a larger population should be observed and clinical diagnostics for measles defined.
